Connect With Us
Subscribe Now
Log In
Home
News
Education
Health
Tech
STEM
Advanced Manufacturing & Logistics
Life Sciences
Ag INnovation
INPower
Videos
Big Wigs
Submit Big Wigs
Events
Innovate Southwest Indiana â Evansville
Innovate West Central Indiana – Terre Haute
Innovate East Central – Muncie
Innovate Northeast Indiana – Fort Wayne
Newsletters
Podcasts
On-Air
TV & Radio Listings
Content Studio
Sponsored Content
Contact
About IIB
Meet the Team
Contact Us
Advertise
Gift Cards
Flagship Stations
Gerry’s Message
Speaking Engagement Request
Search
GO
Connect With Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Acumen Pharmaceuticals, Inc. - Common Stock
(NQ:
ABOS
)
0.2138
-0.0025 (-1.16%)
Delayed Quote
Updated: 4:00 PM EST, Nov 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Acumen Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Unusual-Volume Stocks: Latest Session's Sharp Declines and Double-Digit Gains
↗
Today 13:00 EST
Via
Chartmill
Acumen Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
↗
November 04, 2026
A single confirmatory Phase III trial design could streamline the path to regulatory approval if November data validates the oligomer-targeting approach.
Via
The Motley Fool
Topics
Earnings
US Unusual Volume Stocks: ONEG, CENN, SLGB and INLF in Latest Scan
↗
November 02, 2026
Via
Chartmill
Small-Cap Market Movers: Top Gainers and Losers on Nov. 2, 2026
↗
November 02, 2026
Via
Chartmill
Acumen Pharmaceuticals (NASDAQ:ABOS) Narrows Q3 Loss as ALTITUDE-AD Readout Looms
↗
October 26, 2026
Via
Chartmill
Acumen Pharmaceuticals (NASDAQ:ABOS) Q1 2026 Loss Narrows as Phase 2 Alzheimer's Trial Readout Looms
↗
May 12, 2026
Via
Chartmill
Acumen Pharmaceuticals Inc (NASDAQ:ABOS) Reports Narrower-Than-Expected Q4 Loss, Provides Key Clinical Update
↗
March 26, 2026
Via
Chartmill
Earnings Scheduled For November 12, 2025
↗
November 12, 2025
Via
Benzinga
Postmarket Movers: After-Hours Gainers and Losers
↗
October 30, 2026
Via
Chartmill
Most Active Stocks on Oct. 30, 2026: Intel, ChowChow Cloud and Acumen in Focus
↗
October 30, 2026
Via
Chartmill
Acumen Pharmaceuticals (ABOS) Q3 2026 Earnings Call Transcript
↗
October 26, 2026
Sabirnetug topline results expected November 2026 for early Alzheimer's disease trial.
Via
The Motley Fool
Topics
Earnings
Acumen Pharmaceuticals Q3 Earnings Call Highlights
↗
October 26, 2026
Acumen Pharmaceuticals (NASDAQ:ABOS) said it expects to report top-line results in November from its Phase II ALTITUDE-AD trial of sabirnetug, an investigational antibody designed to target soluble...
Via
MarketBeat
Topics
Earnings
Acumen Pharmaceuticals's Earnings: A Preview
↗
August 11, 2025
Via
Benzinga
A Preview Of Acumen Pharmaceuticals's Earnings
↗
May 12, 2025
Via
Benzinga
Acumen Pharmaceuticals Q2 Earnings Call Highlights
↗
August 12, 2026
Acumen Pharmaceuticals (NASDAQ:ABOS) said it remains on track to report top-line results late in 2026 from its Phase II ALTITUDE-AD study of sabirnetug, an investigational antibody designed to...
Via
MarketBeat
Topics
Earnings
Acumen (ABOS) Q1 2026 Earnings Transcript
↗
May 12, 2026
Acumen (ABOS) Q1 2026 Earnings Transcript
Via
The Motley Fool
Acumen Pharmaceuticals Q1 Earnings Call Highlights
↗
May 12, 2026
Acumen Pharmaceuticals (NASDAQ:ABOS) said its Phase 2 ALTITUDE-AD trial of sabirnetug remains on track, with top-line results expected late in 2026, as the company continues to advance its broader...
Via
MarketBeat
Topics
Earnings
Preview: Acumen Pharmaceuticals's Earnings
↗
March 26, 2025
Via
Benzinga
Earnings Scheduled For November 12, 2024
↗
November 12, 2024
Via
Benzinga
Acumen Pharmaceuticals Earnings Preview
↗
November 11, 2024
Via
Benzinga
These stocks have an unusual volume in today's session
↗
January 28, 2026
Via
Chartmill
Tuesday's after hours session: top gainers and losers
↗
January 27, 2026
Via
Chartmill
The market is filled with gapping stocks in Monday's session.
↗
January 26, 2026
Via
Chartmill
Acumen Pharmaceuticals Inc (NASDAQ:ABOS) Reports Q3 2025 Earnings, Beats EPS Estimates
↗
November 12, 2025
Acumen Pharmaceuticals posts better-than-expected Q3 2025 results, advancing its Alzheimer's treatment pipeline with cash into 2027.
Via
Chartmill
Topics
Earnings
Preview: Acumen Pharmaceuticals's Earnings
↗
November 11, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
September 25, 2025
Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The market value of their outstanding shares is at $87.2 million.
Via
Benzinga
Tesla To $345? Here Are 10 Top Analyst Forecasts For Friday
↗
March 28, 2025
Via
Benzinga
Earnings Scheduled For August 12, 2025
↗
August 12, 2025
Via
Benzinga
Earnings Scheduled For May 13, 2025
↗
May 13, 2025
Via
Benzinga
Earnings Scheduled For March 27, 2025
↗
March 27, 2025
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
